Sun Pharma Shares Rise After FDA Approval For Cancer Drug

By Admin
Share
The firm, which is headquartered in Mumbai released a statement saying that its subsidiary has received the green light for US Food and Drug Administr...

 

The firm, which is headquartered in Mumbai released a statement saying that its subsidiary has received the green light for US Food and Drug Administration for its Doxorubicin HCI Liposome Injection.  

“This generic Doxorubicin HCl Liposome injection USP, 2 mg/ml is therapeutically equivalent to Doxil Liposome Injection, 2 mg/ml of Janssen Research and Development, LLC,” the company said.

Doxorubicin HCl liposome injection is used to treat patients with ovarian cancer, which has progressed or recurred after platinum-based chemotherapy.

Reacting to the development, shares of Sun Pharma were trading at Rs 745.70 on the BSE in afternoon trade, up 3.84 percent from their previous close. 

Share

Featured Articles

SAVE THE DATE – Healthcare LIVE Global 2025

Healthcare Digital is excited to announce the launch of Healthcare LIVE Global for 2025

How Huawei's Digital Solutions are Transforming Healthcare

Offering network, cloud, and AI solutions, Huawei is able to help healthcare providers deliver better outcomes for patients

2024 Nestlé Nutrition Symposium Explored Food & Health

Nestlé manufactures 4.5m KitKats every day, but the food giant is also focused on advancing food nutrition, as explored at the 2024 International Symposium

Thirona’s AI Tech is Creating Individualised Patient Care

Technology & AI

AstraZeneca’s Discovery Centre, Constructed by Mace Group

Technology & AI

NeoGenomics: Data in Oncology Testing & Diagnostics

AI & ML